Introduction
Interstitial cystitis (IC) is considered a rare disorder and poor understanding of the underlying causes of the disorder have made diagnosis and management difficult. Moreover, this has impacted on the development of effective drugs for this disorderthere are few available treatments for IC and as a result, significant unmet needs exist.Scope
- Quantitative treatment data from 190 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
- Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to second-line treatments for IC
- Influences on treatment choice and perception of current drug therapies including pentosan polysulfate sodium and the antimuscarinics
- Influences on treatment choice and perception of current drug therapies, unmet needs and future outlook including the R&D drug pipeline
Highlights
Presentation rates for IC are higher than in other OAB disorders due to the patient experience of pain. However, discord in the terminology and diagnostic criteria for IC confound diagnosis; and as result, the diagnosis of IC tends to be one of exclusion, and as such can take many years to be reached, bringing unnecessary suffering to the patient.IC symptoms have a similar terminology to those of Overactive Bladder, but are fundamentally different. Poor understanding of the disorder and limited treatment options means that many physicians have resorted to using antimuscarinics despite their limited proven efficacy in treating the pain.
Further research into the etiology of IC is the key to finding a truly effective treatment for IC that works. In the meantime, companies wishing to target the IC market should aim to demonstrate the ability of their drug to treat pain in addition to urgency and frequency.
Reasons to Purchase
- Forecast product sales by understanding key aspects of IC epidemiology, diagnosis and treatment
- Gain a better understanding of the challenges facing current and future players in the IC market
- Identify physicians key concerns in IC including unmet needs and the attributes that physicians believe are desirable for future treatments
OVERVIEW 6
This product has been designed for delivery in a slide pack format (PowerPoint). 6
Please select the slide pack option from the download menu at the side of the page 6
Introduction 6
Scope of this report 6
Research and analysis highlights 7
Key reasons to read this report 7
APPENDIX A 8
Research methodology 8
Physician Sample breakdown 8
Urinary Incontinence and Overactive Bladder Insight Study – Physician Questionnaire 9
Section One Overview of Urinary Incontinence and overactive Bladder 9
Epidemiology 9
Presentation 10
Diagnosis 11
Referral pattern 11
Section Two Stress Urinary Incontinence 14
Diagnosis and treatment of SUI 14
Non-pharmacological treatment 15
Pharmacological treatment for SUI 16
Section Three Overactive Bladder With Urge Symptoms and/or Incontinence 19
Diagnosis and treatment of UUI 19
Pharmacological treatment for UUI 20
Diagnosis and treatment of ’dry OAB’ 23
Pharmacological treatment for dry OAB 24
Section Four Mixed Stress/Urge Urinary Incontinence 27
Diagnosis and treatment of mixed SUI/UUI 27
Non-pharmacological treatment 29
Pharmacological treatment for mixed SUI/UUI 30
Section Five Interstitial Cystitis 33
Diagnosis and treatment of IC 33
Pharmacological treatment for IC 33
Section Six Drug Profiles 37
Section A: Drug influences on physicians’ choice 37
Section B: The general treatment of urinary incontinence and overactive bladder 44
Contributing experts 46
US 46
Japan 46
Europe 47
APPENDIX B 48
About Datamonitor 48
About Datamonitor Healthcare 48
About the CNS analysis team 49
Disclaimer 50
Other selected research from the 'Other' category:
Financial Markets Research: Palatin Technologies’ Bremelanotide - Competition and regulatory risk cloud potential
Partneringreview 2006 Vol 2 Ch 9: Musculoskeletal (PR06V2C09)